Establishment Labs (NASDAQ:ESTA) Stock Price Down 5.6%

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTAGet Free Report) fell 5.6% during mid-day trading on Thursday . The company traded as low as $44.26 and last traded at $44.76. 166,688 shares changed hands during mid-day trading, a decline of 56% from the average session volume of 379,591 shares. The stock had previously closed at $47.43.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ESTA. Citigroup cut Establishment Labs from a “buy” rating to a “neutral” rating and set a $60.00 price target for the company. in a report on Wednesday, May 22nd. Mizuho boosted their target price on shares of Establishment Labs from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, June 6th. Finally, JPMorgan Chase & Co. raised their price target on shares of Establishment Labs from $46.00 to $53.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $56.00.

View Our Latest Research Report on ESTA

Establishment Labs Stock Performance

The firm has a market cap of $1.23 billion, a PE ratio of -14.24 and a beta of 1.22. The stock has a 50-day moving average price of $52.30 and a 200 day moving average price of $41.83. The company has a debt-to-equity ratio of 3.38, a current ratio of 4.24 and a quick ratio of 2.73.

Establishment Labs (NASDAQ:ESTAGet Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.07. The company had revenue of $37.17 million during the quarter, compared to analysts’ expectations of $35.61 million. Establishment Labs had a negative return on equity of 206.05% and a negative net margin of 53.12%. The firm’s revenue was down 20.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.48) EPS. Research analysts forecast that Establishment Labs Holdings Inc. will post -1.79 earnings per share for the current year.

Hedge Funds Weigh In On Establishment Labs

Institutional investors and hedge funds have recently bought and sold shares of the stock. Baker Avenue Asset Management LP acquired a new stake in shares of Establishment Labs during the 3rd quarter worth $59,000. J.P. Morgan Private Wealth Advisors LLC raised its holdings in Establishment Labs by 28.9% in the third quarter. J.P. Morgan Private Wealth Advisors LLC now owns 6,200 shares of the company’s stock valued at $304,000 after buying an additional 1,389 shares during the period. Clear Street Markets LLC purchased a new stake in Establishment Labs during the third quarter worth approximately $88,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Establishment Labs by 67.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,591 shares of the company’s stock worth $119,000 after buying an additional 1,845 shares during the period. Finally, California State Teachers Retirement System increased its position in shares of Establishment Labs by 14.5% in the first quarter. California State Teachers Retirement System now owns 17,096 shares of the company’s stock worth $870,000 after acquiring an additional 2,167 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

About Establishment Labs

(Get Free Report)

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

See Also

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.